Form 4/A for ELVN Enliven Therapeutics, Inc.
Accepted 2025-08-21 00:00:00 ET · period of report 2025-08-18 · accession 0001415889-25-022649 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AI | 2025-08-21 | 2025-08-20 | ELVN | Kintz Samuel | Pres AND CEO, Dir | S - Sale | $20.00 | -1,517 | 927.9K | -0.2% | -$30.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-20 | S | D | 1,517 | $20.00 | 927,892 | I See footnote | — | — | (F1) The original Form 4, filed August 20, 2025, did not reflect the stock sale on August 20, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $20.00 to $20.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F4) The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. |